Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29711858 | 1.00 | CDC7 (0.49) | CDC7CDK2ROCK1BIRC5KDM4E | |
| SCHEMBL2396805 | 0.87 | PRKD3 (0.46) | CDC7CDK2ROCK1BIRC5KDM4E | |
| Hydrochloric Acid SCHEMBL4557116 | 0.85 | PRKD3 (0.45) | CDC7CDK2ROCK1BIRC5KDM4E | |
| SCHEMBL2672479 | 0.82 | CDC7 (0.44) | CDC7CDK2ROCK1BIRC5PRKD3 | |
| SCHEMBL28511790 | 0.79 | ROCK1 (0.42) | CDC7CDK2ROCK1BIRC5KDM4E | |
| SCHEMBL29711844 | 0.79 | BIRC5 (0.56) | CDC7CDK2ROCK1BIRC5PRKD3 | |
| SCHEMBL7610161 | 0.79 | CDC7 (0.49) | CDC7CDK2ROCK1BIRC5MAPT | |
| SCHEMBL31454921 | 0.79 | CDC7 (0.51) | CDC7CDK2ROCK1KDM4EGAA | |
| SCHEMBL31454927 | 0.79 | CDC7 (0.51) | CDC7CDK2ROCK1BIRC5KDM4E | |
| SCHEMBL31454972 | 0.79 | BIRC5 (0.44) | CDC7CDK2ROCK1BIRC5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115991707-A | Preparation method of indoloquinoxaline compound | 西安凯翔生物医药科技有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115991707-A | Preparation method of indoloquinoxaline compound | 西安凯翔生物医药科技有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115991707-A | Preparation method of indoloquinoxaline compound | 西安凯翔生物医药科技有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| CN-1854128-B | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY | 2012-05-16 | — | — | CN | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| CN-1518534-A | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | 麻省理工学院 | 2004-08-04 | — | — | CN | disclosed |
| US-6759554-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-07-06 | — | — | US | disclosed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1303508-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)INDOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6353007-B1 | ANTIINFLAMMATORY AGENTS AND INHIBITORS OF CELLULAR POLIFERATION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2002006273-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)INDOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0812319-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | CDC7 2487/4885CDK2 2079/4885ROCK1 1783/4885 |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CDC7 3860/4885CDK2 1121/4885ROCK1 4417/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CDC7 3860/4885CDK2 1121/4885ROCK1 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.